(Q63831488)
Statements
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis (English)
0 references
March 2010
0 references
December 2012
0 references
32
0 references
18 year
0 references
65 year
0 references